The PD-1 Axis Enforces an Anatomical Segregation of CTL Activity that Creates Tumor Niches after Allogeneic Hematopoietic Stem Cell Transplantation

Immunity

Volumn 44, Issue 1, 2016, Pages 143-154

  Michonneau, David ^a,b,c   Sagoo, Pervinder ^a,b   Breart, Béatrice ^a,b   Garcia, Zacarias ^a,b   Celli, Susanna ^a,b   Bousso, Philippe ^a,b  

^a INSTITUT PASTEUR   (France)

^b INSTITUT PASTEUR   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; PROGRAMMED DEATH 1 RECEPTOR; PDCD1 PROTEIN, MOUSE;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER RECURRENCE; CD8+ T LYMPHOCYTE; CELL COMPARTMENTALIZATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOLOGIC MALIGNANCY; LYMPH NODE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE SPECIFICITY; TUMOR ESCAPE; TUMOR MICROENVIRONMENT; ALLOGRAFT; ANIMAL; C57BL MOUSE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; GRAFT VERSUS TUMOR EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; KNOCKOUT MOUSE; TRANSGENIC MOUSE;

ALLOGRAFTS; ANIMALS; FEMALE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; GRAFT VS HOST DISEASE; GRAFT VS TUMOR EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; PROGRAMMED CELL DEATH 1 RECEPTOR; T-LYMPHOCYTES, CYTOTOXIC; TUMOR ESCAPE;

EID: 84958886609     PISSN: 10747613     EISSN: 10974180     Source Type: Journal    
DOI: 10.1016/j.immuni.2015.12.008     Document Type: Article

References (50)

1. Adams J.M., Harris A.W., Pinkert C.A., Corcoran L.M., Alexander W.S., Cory S., Palmiter R.D., Brinster R.L. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 1985, 318:533-538.
2. Al-Chaqmaqchi H., Sadeghi B., Abedi-Valugerdi M., Al-Hashmi S., Fares M., Kuiper R., Lundahl J., Hassan M., Moshfegh A. The role of programmed cell death ligand-1 (PD-L1/CD274) in the development of graft versus host disease. PLoS ONE 2013, 8:e60367.
3. Armand P., Nagler A., Weller E.A., Devine S.M., Avigan D.E., Chen Y.-B., Kaminski M.S., Holland H.K., Winter J.N., Mason J.R., et al. Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. J. Clin. Oncol. 2013, 31:4199-4206.
4. Asakura S., Hashimoto D., Takashima S., Sugiyama H., Maeda Y., Akashi K., Tanimoto M., Teshima T. Alloantigen expression on non-hematopoietic cells reduces graft-versus-leukemia effects in mice. J. Clin. Invest. 2010, 120:2370-2378.
5. Bennett C.L., Fallah-Arani F., Conlan T., Trouillet C., Goold H., Chorro L., Flutter B., Means T.K., Geissmann F., Chakraverty R. Langerhans cells regulate cutaneous injury by licensing CD8 effector cells recruited to the skin. Blood 2011, 117:7063-7069.
6. Blazar B.R., Carreno B.M., Panoskaltsis-Mortari A., Carter L., Iwai Y., Yagita H., Nishimura H., Taylor P.A. Blockade of programmed death-1 engagement accelerates graft-versus-host disease lethality by an IFN-gamma-dependent mechanism. J. Immunol. 2003, 171:1272-1277.
7. Bourgeois C., Rocha B., Tanchot C. A role for CD40 expression on CD8+ T cells in the generation of CD8+ T cell memory. Science 2002, 297:2060-2063.
8. Brahmer J.R., Drake C.G., Wollner I., Powderly J.D., Picus J., Sharfman W.H., Stankevich E., Pons A., Salay T.M., McMiller T.L., et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 2010, 28:3167-3175.
9. Chakraverty R., Côté D., Buchli J., Cotter P., Hsu R., Zhao G., Sachs T., Pitsillides C.M., Bronson R., Means T., et al. An inflammatory checkpoint regulates recruitment of graft-versus-host reactive T cells to peripheral tissues. J. Exp. Med. 2006, 203:2021-2031.
10. Cooke K.R., Kobzik L., Martin T.R., Brewer J., Delmonte J., Crawford J.M., Ferrara J.L. An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin. Blood 1996, 88:3230-3239.
11. Dermime S., Mavroudis D., Jiang Y.Z., Hensel N., Molldrem J., Barrett A.J. Immune escape from a graft-versus-leukemia effect may play a role in the relapse of myeloid leukemias following allogeneic bone marrow transplantation. Bone Marrow Transplant. 1997, 19:989-999.
12. + T cell tolerance. J. Exp. Med. 2014, 211:1153-1166.
13. Ferrara J.L.M., Levine J.E., Reddy P., Holler E. Graft-versus-host disease. Lancet 2009, 373:1550-1561.
14. Fife B.T., Pauken K.E., Eagar T.N., Obu T., Wu J., Tang Q., Azuma M., Krummel M.F., Bluestone J.A. Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. Nat. Immunol. 2009, 10:1185-1192.
15. Flies D.B., Wang S., Xu H., Chen L. Cutting edge: A monoclonal antibody specific for the programmed death-1 homolog prevents graft-versus-host disease in mouse models. J. Immunol. 2011, 187:1537-1541.
16. Flutter B., Edwards N., Fallah-Arani F., Henderson S., Chai J.-G., Sivakumaran S., Ghorashian S., Bennett C.L., Freeman G.J., Sykes M., Chakraverty R. Nonhematopoietic antigen blocks memory programming of alloreactive CD8+ T cells and drives their eventual exhaustion in mouse models of bone marrow transplantation. J. Clin. Invest. 2010, 120:3855-3868.
17. Goulmy E., Termijtelen A., Bradley B.A., van Rood J.J. Y-antigen killing by T cells of women is restricted by HLA. Nature 1977, 266:544-545.
18. Goulmy E., Schipper R., Pool J., Blokland E., Falkenburg J.H., Vossen J., Gratwohl A., Vogelsang G.B., van Houwelingen H.C., van Rood J.J. Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. N. Engl. J. Med. 1996, 334:281-285.
19. Gratwohl A., Baldomero H., Gratwohl M., Aljurf M., Bouzas L.F., Horowitz M., Kodera Y., Lipton J., Iida M., Pasquini M.C., et al. Quantitative and qualitative differences in use and trends of hematopoietic stem cell transplantation: a Global Observational Study. Haematologica 2013, 98:1282-1290. Worldwide Network of Blood and Marrow Transplantation (WBMT).
20. Guarda G., Hons M., Soriano S.F., Huang A.Y., Polley R., Martín-Fontecha A., Stein J.V., Germain R.N., Lanzavecchia A., Sallusto F. L-selectin-negative CCR7- effector and memory CD8+ T cells enter reactive lymph nodes and kill dendritic cells. Nat. Immunol. 2007, 8:743-752.
21. Hamid O., Robert C., Daud A., Hodi F.S., Hwu W.-J., Kefford R., Wolchok J.D., Hersey P., Joseph R.W., Weber J.S., et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med. 2013, 369:134-144.
22. Harris A.C., Kitko C.L., Couriel D.R., Braun T.M., Choi S.W., Magenau J., Mineishi S., Pawarode A., Yanik G., Levine J.E. Extramedullary relapse of acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation: incidence, risk factors and outcomes. Haematologica 2013, 98:179-184.
23. Honda T., Egen J.G., Lämmermann T., Kastenmüller W., Torabi-Parizi P., Germain R.N. Tuning of antigen sensitivity by T cell receptor-dependent negative feedback controls T cell effector function in inflamed tissues. Immunity 2014, 40:235-247.
24. Hufford M.M., Kim T.S., Sun J., Braciale T.J. Antiviral CD8+ T cell effector activities in situ are regulated by target cell type. J. Exp. Med. 2011, 208:167-180.
25. Klein I., Crispe I.N. Complete differentiation of CD8+ T cells activated locally within the transplanted liver. J. Exp. Med. 2006, 203:437-447.
26. Koestner W., Hapke M., Herbst J., Klein C., Welte K., Fruehauf J., Flatley A., Vignali D.A., Hardtke-Wolenski M., Jaeckel E., et al. PD-L1 blockade effectively restores strong graft-versus-leukemia effects without graft-versus-host disease after delayed adoptive transfer of T-cell receptor gene-engineered allogeneic CD8+ T cells. Blood 2011, 117:1030-1041.
27. Lochner M., Peduto L., Cherrier M., Sawa S., Langa F., Varona R., Riethmacher D., Si-Tahar M., Di Santo J.P., Eberl G. In vivo equilibrium of proinflammatory IL-17+ and regulatory IL-10+ Foxp3+ RORgamma t+ T cells. J. Exp. Med. 2008, 205:1381-1393.
28. Macleod B.L., Bedoui S., Hor J.L., Mueller S.N., Russell T.A., Hollett N.A., Heath W.R., Tscharke D.C., Brooks A.G., Gebhardt T. Distinct APC subtypes drive spatially segregated CD4+ and CD8+ T-cell effector activity during skin infection with HSV-1. PLoS Pathog. 2014, 10:e1004303.
29. Matte-Martone C., Venkatesan S., Tan H.S., Athanasiadis I., Chang J., Pavisic J., Shlomchik W.D. Graft-versus-leukemia (GVL) against mouse blast-crisis chronic myelogenous leukemia (BC-CML) and chronic-phase chronic myelogenous leukemia (CP-CML): shared mechanisms of T cell killing, but programmed death ligands render CP-CML and not BC-CML GVL resistant. J. Immunol. 2011, 187:1653-1663.
30. Mempel T.R., Pittet M.J., Khazaie K., Weninger W., Weissleder R., von Boehmer H., von Andrian U.H. Regulatory T cells reversibly suppress cytotoxic T cell function independent of effector differentiation. Immunity 2006, 25:129-141.
31. Miklos D.B., Kim H.T., Miller K.H., Guo L., Zorn E., Lee S.J., Hochberg E.P., Wu C.J., Alyea E.P., Cutler C., et al. Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood 2005, 105:2973-2978.
32. Mutis T., Gillespie G., Schrama E., Falkenburg J.H., Moss P., Goulmy E. Tetrameric HLA class I-minor histocompatibility antigen peptide complexes demonstrate minor histocompatibility antigen-specific cytotoxic T lymphocytes in patients with graft-versus-host disease. Nat. Med. 1999, 5:839-842.
33. Nakasone H., Tian L., Sahaf B., Kawase T., Schoenrock K., Perloff S., Ryan C.E., Paul J., Popli R., Wu F., et al. Allogeneic HY antibodies detected 3 months after female to male sex-mismatched HCT predict chronic GVHD and non-relapse mortality. Blood 2015, 125:3193-3201.
34. Norde W.J., Maas F., Hobo W., Korman A., Quigley M., Kester M.G.D., Hebeda K., Falkenburg J.H.F., Schaap N., de Witte T.M., et al. PD-1/PD-L1 interactions contribute to functional T-cell impairment in patients who relapse with cancer after allogeneic stem cell transplantation. Cancer Res. 2011, 71:5111-5122.
35. Pasquini M., Wang Z., Horowitz M.M., Gale R.P. 2013 report from the Center for International Blood and Marrow Transplant Research (CIBMTR): current uses and outcomes of hematopoietic cell transplants for blood and bone marrow disorders. Clin. Transpl. 2013, 187-197.
36. Sackstein R. A revision of Billingham's tenets: the central role of lymphocyte migration in acute graft-versus-host disease. Biol. Blood Marrow Transplant. 2006, 12(1, Suppl 1):2-8.
37. Saha A., Aoyama K., Taylor P.A., Koehn B.H., Veenstra R.G., Panoskaltsis-Mortari A., Munn D.H., Murphy W.J., Azuma M., Yagita H., et al. Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality. Blood 2013, 122:3062-3073.
38. Schilbach K., Schick J., Wehrmann M., Wollny G., Simon P., Schlegel P.G., Eyrich M. PD-1-PD-L1 pathway is involved in suppressing alloreactivity of heart infiltrating t cells during murine gvhd across minor histocompatibility antigen barriers. Transplantation 2007, 84:214-222.
39. Schneidawind D., Pierini A., Negrin R.S. Regulatory T cells and natural killer T cells for modulation of GVHD following allogeneic hematopoietic cell transplantation. Blood 2013, 122:3116-3121.
40. Sega E.I., Leveson-Gower D.B., Florek M., Schneidawind D., Luong R.H., Negrin R.S. Role of lymphocyte activation gene-3 (Lag-3) in conventional and regulatory T cell function in allogeneic transplantation. PLoS ONE 2014, 9:e86551.
41. Shand J.C., Qin H., Nasholm N., Capitini C.M., Fry T.J. Minor antigen distribution predicts site-specific graft-versus-tumor activity of adoptively transferred, minor antigen-specific CD8 T Cells. Biol. Blood Marrow Transplant. 2014, 20:26-36.
42. Shimizu H., Saitoh T., Hatsumi N., Takada S., Handa H., Jimbo T., Sakura T., Miyawaki S., Nojima Y. Prevalence of extramedullary relapses is higher after allogeneic stem cell transplantation than after chemotherapy in adult patients with acute myeloid leukemia. Leuk. Res. 2013, 37:1477-1481.
43. Tewalt E.F., Cohen J.N., Rouhani S.J., Guidi C.J., Qiao H., Fahl S.P., Conaway M.R., Bender T.P., Tung K.S., Vella A.T., et al. Lymphatic endothelial cells induce tolerance via PD-L1 and lack of costimulation leading to high-level PD-1 expression on CD8 T cells. Blood 2012, 120:4772-4782.
44. Tiegs G., Lohse A.W. Immune tolerance: what is unique about the liver. J. Autoimmun. 2010, 34:1-6.
45. Toubai T., Tawara I., Sun Y., Liu C., Nieves E., Evers R., Friedman T., Korngold R., Reddy P. Induction of acute GVHD by sex-mismatched H-Y antigens in the absence of functional radiosensitive host hematopoietic-derived antigen-presenting cells. Blood 2012, 119:3844-3853.
46. Valujskikh A., Lantz O., Celli S., Matzinger P., Heeger P.S. Cross-primed CD8(+) T cells mediate graft rejection via a distinct effector pathway. Nat. Immunol. 2002, 3:844-851.
47. Veenstra R.G., Taylor P.A., Zhou Q., Panoskaltsis-Mortari A., Hirashima M., Flynn R., Liu D., Anderson A.C., Strom T.B., Kuchroo V.K., Blazar B.R. Contrasting acute graft-versus-host disease effects of Tim-3/galectin-9 pathway blockade dependent upon the presence of donor regulatory T cells. Blood 2012, 120:682-690.
48. Vincent K., Roy D.-C., Perreault C. Next-generation leukemia immunotherapy. Blood 2011, 118:2951-2959.
49. Wilhelm K., Ganesan J., Müller T., Dürr C., Grimm M., Beilhack A., Krempl C.D., Sorichter S., Gerlach U.V., Jüttner E., et al. Graft-versus-host disease is enhanced by extracellular ATP activating P2X7R. Nat. Med. 2010, 16:1434-1438.
50. Zinselmeyer B.H., Heydari S., Sacristán C., Nayak D., Cammer M., Herz J., Cheng X., Davis S.J., Dustin M.L., McGavern D.B. PD-1 promotes immune exhaustion by inducing antiviral T cell motility paralysis. J. Exp. Med. 2013, 210:757-774.